Comparison of efficacies of dual therapy and triple therapy using rabeprazole in second-line eradication of Helicobacter pylori in Japan

Alimentary Pharmacology and Therapeutics Symposium Series

Volumn 2, Issue 1, 2006, Pages 16-22

  Kawai, T ^a,b   Kawakami, K ^b   Kataoka, M ^b   Taira, S ^b   Itoi, T ^b   Moriyasu, F ^b   Takagi, Y ^b   Aoki, T ^b   Rimbara, E ^c   Noguchi, N ^c   Sasatsu, M ^c  

^a Tokyo Medical University ^*  (Japan)

^b TOKYO MEDICAL UNIVERSITY   (Japan)

^c TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CARBON 13; CYTOCHROME P450 2C19; METRONIDAZOLE; RABEPRAZOLE; UREA;

ADULT; ANALYTIC METHOD; BACTERIAL INFECTION; BLOATING; CLINICAL TRIAL; COMPARATIVE STUDY; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SENSITIVITY; EPIGASTRIC DISCOMFORT; ERADICATION THERAPY; FEMALE; HEARTBURN; HELICOBACTER PYLORI; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; TASTE DISORDER;

EID: 34247855877     PISSN: 17466334     EISSN: 17466342     Source Type: Journal    
DOI: 10.1111/j.1746-6342.2006.00021.x     Document Type: Conference Paper

References (47)

1. Marshall BJ, Goodwin CS, Warren JR, et al. Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet 1988 2:1437 42.
2. Malfertheiner P, Leodolter A, Peitz U. Cure of Helicobacter pylori-associated ulcer disease through eradication. Baillieres Best Pract Res Clin Gastroenterol 2000 14:119 32.
3. Parsonnet J, Friedman GD, Vandersteen DP, et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med 1991 325:1127 31.
4. Lind T, Veldhuyzen Zanten van S, Unge P, et al. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH 1 study. Helicobacter 1996 1:138 44.
5. Bazzoli F, Zagari M, Pozzato P, et al. Evaluation of short-term low-dose triple therapy for the eradication of Helicobacter pylori by factorial design in a randomized, double blind, control study. Aliment Pharmacol Ther 1998 12:439 45.
6. The European Helicobacter Pylori Study Group. Current European concepts in the management of Helicobacter pylori infection. The Masstricht Consensus Report. Gut 1997 41:8 13.
7. Miwa H, Ohkura R, Murai T, et al. Impact of rabeprazole, a new proton pump inhibitor, in triple therapy for Helicobacter pylori infection: comparison with omeprazole and lansoprazole. Aliment Pharmacol Ther 1999 13:741 6.
8. Rinnaldi V, Zullo A, De Francesco V, et al. Helicobacter pylori eradication with proton pump inhibitor-based triple therapies and re-treatment with ranitidine bismuth citrate-based triple therapy. Aliment Pharmacol Ther 1999 13:163 8.
9. Tursi A, Brandimarte G, Giorgetti G, Modeo ME, Gigliobianco A. Efficacy and tolerability of ranitidine bismuth citrate plus amoxicillin and clarithromycin as first- or second-line therapies to cure Helicobacter pylori infection. Hepatogastroenterology 2002 46:1006 9.
10. De Boer WA, Borody TJ. Treatment failures and secondary resistance to antibiotics. A growing concern in Helicobacter pylori therapy. Dig Liver Dis 2000 32:673 5.
11. Gisbert JP, Boixeda D, Bermejo F, et al. Re-treatment after Helicobacter pylori eradication failure. Eur J Gastroenterol Hepatol 1999 11:1049 54.
12. Lin CK, Hsu PI, Lai KH, et al. One-week quadruple therapy is an effective salvage regimen for Helicobacter pylori infection in patients after failure of standard triple therapy. J Clin Gastroenterol 2002 34:547 51.
13. Ohara S, Kato M, Asaka M, Toyota T. Studies of 13C-urea breath test for diagnosis of Helicobacter pylori infection in Japan. J Gastroenterol 1998 33:6 13.
14. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing. Twelfth Informational Supplement, M100-S12. Viillanova, PA:NCCLS, 2002.
15. De Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994 269:15419 22.
16. De Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. Identification of new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994 46:594 8.
17. Hojo M, Miwa H, Nagahara A, Sato N. Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection. Scand J Gastroenterol 2001 36:690 700.
18. Miwa H, Misawa H, Yamada T, Nagahara A, Ohtaka K, Sato N. Clarithromycin resistance, but not CYP2C19 polymorphrism, has a major impact on treatment success in 7-day treatment regimen for the cure of H. pylori infection. Dig Dis Sci 2001 46:2445 50.
19. Murakami K, Sato R, Okimoto T, et al. Efficacy of triple therapy comprising rabeprazole, amoxicillin and metronidazole for second-line Helicobacter pylori eradication in Japan, and the influence of metronidazole resistance. Aliment Pharmacol Ther 2003 17:119 23.
20. Tankovic J, Lamarque D, Lascols C, Soussy CJ, Delchier DJ. Impact of Helicobacter pylori resistance to clarithromycin on the efficacy of the omeprazole-amoxicillin-clarithromycin therapy. Aliment Pharmacol Ther 2001 5:707 13.
21. Ducons JA, Santolaria S, Guirao R, Ferrero M, Montoro M, Gomollon F. Impact of clarithromycin resistance on the effectiveness of regimen for Helicobacter pylori: a prospective study of 1-week lansoprazole, amoxicillin and clarithromycin in active peptic ulcers. Aliment Pharmacol Ther 1999 13:775 80.
22. Yasuda S, Horai Y, Tomono Y, et al. Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4′-hydroxylation status. Clin Pharmacol Ther 1995 58:143 54.
23. Ishizaki T, Horai Y. Cytochrome P450 and the metabolism of proton pump inhibitors: emphasis on rabeprazole (Review Article). Aliment Pharmacol Ther 1999 13 (Suppl. 3 27 36.
24. Williams MP, Sercombe J, Hamilton MI, Pounder RE. A placebo-controlled trial to assess the effects of 8-day dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects. Aliment Pharmacol Ther 1998 12:1079 89.
25. Stack WA, Knifton A, Thirlwell D, et al. Safety and efficacy of rabeprazole in combination with four antibiotic regimens for the eradication of Helicobacter pylori in patients with chronic gastritis with or without peptic ulceration. Am J Gastroenterol 1998 93:1909 13.
26. Kihira K, Satoh K, Saifuku K, et al. Rabeprazole, amoxycillin and low- or high-dose clarithromycin for the cure of Helicobacter pylori. Aliment Pharmacol Ther 2000 14:1083 7.
27. Inaba T, Mizuno M, Kawai K, et al. Randomized open trial for comparison of proton pump inhibitors in triple therapy. J Gastroenterol Hepatol 2002 17:748 53.
28. Furuta T, Shirai N, Takashima M, et al. Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy rabeprazole plus amoxicillin. Pharmacogenetics 2001 11:1 8.
29. Kawai T, Oguma K, Kudo T, et al. Comparison of dual therapy of rabeprazole plus amoxicillin and triple therapy for the cure of Helicobacter pylori infection. Gastroenterology 2001 118:A498.
30. Rinaldi V, Zullo A, Pugliano F, Valente C, Diana F, Attili AF. The management of failed dual or triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 1997 11:929 33.
31. Ellenrieder V, Boeck W, Richter C, Marre R, Adler G, Glasbrenner B. Prevalence of resistance to clarithromycin and its clinical impact on the efficacy of Helicobacter pylori eradication. Scand J Gastroenterol 1999 34:750 56.
32. Fujisaki H, Shibata H, Oketani K, et al. Inhibitions of acid secretion by E3810 and omeprazole, and their reversal by glutathione. Biochem Pharmacol 1991 42:321 8.
33. Besancon M, Simon A, Sachs G, Shin JM. Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents. J Biol Chem 1997 272:438 46.
34. Ohara T, Goshi S, Taneike I, Tamura Y, Zhang HM, Yamamoto T. Inhibitory action of a novel proton pump inhibitor, rabeprazole, and its thioether derivative against the growth and motility of clarithromycin-resistant Helicobacter pylori. Helicobacter 2001 6:125 9.
35. Furuta T, Shirai N, Xiao F, et al. High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual dose of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology 2003 50:2274 8.
36. Isomoto H, Inoue K, Furuso H, et al. High-dose rabeprazole-amoxicillin versus rabeprazole-amoxicillin-metronidazole as second-line treatment after failure of the Japanese standard regimen for Helicobacter pylori infection. Aliment Pharmacol Ther 2003 18:101 7.
37. Nakamura M, Spiller RC, Barrett DA, et al. Gastric juice, gastric tissue and blood antibiotic concentrations following omeprazole, amoxicillin and clarithromycin triple therapy. Helicobacter 2003 4:294 9.
38. Strom M, Solrberg M, Jonsson KA. Immediate repeat course of amoxicillin, metronidazole and omeprazole to eradicate Helicobacter pylori. Aliment Pharmacol Ther 1997 11:311 16.
39. Meguaud F, Lehn N, Lind T, et al. Antimicrobial susceptibility testing of Helicobacter pylori in a large multicenter trial: the MACH 2 Study. Antimicrob Agents Chemother 1999 43:2747 52.
40. Pilotto A, Leandro G, Franceschi M, et al. The effect of antibiotic resistance on the outcome of three 1-week triple therapies against Helicobacter pylori. Aliment Pharmacol Ther 1999 13:667 73.
41. Lamouliatte H, Megraud F, Delchier JC, et al. Second-line treatment for failure to eradicate Helicobacter pylori; a randomized trial comparing treatment strategies. Aliment Pharmacol Ther 2003 18:791 7.
42. Glupcznski Y, Broutet N, Cantagrel A, et al. Comparison of the E test and agar dilution method for antimicrobial susceptibility testing of Helicobacter pylori. Eur J Clin Microbiol Infect Dis 2002 21:549 52.
43. Rinbara E, Noguchi N, Tanabe M, Kawai T, Matsumoto Y, Sasatsu M. Susceptibilities to clarithromycin, amoxicillin and metronidazole of Helicobacter pylori isolated from antrum and corpus in Tokyo, Japan 1995-2001. Clin Microbiol Infect 2005 11:307 11.
44. Nista EC, Candelli M, Cremonini F, et al. Levofloxacin-based triple therapy vs quadruple therapy in second-line Helicobacter pylori treatment: a randomized trial. Aliment Pharmacol Ther 2003 18:627 33.
45. Di Mario F, Orsi P, Pinazzi O, Aragona G. Levofloxacin as rescue treatment for Helicobacter pylori. Gut 2004 53 (Suppl. VI A124.
46. Watanabe Y, Aoyama N, Shirasaka D, et al. Levofloxacin based triple therapy as a second-line treatment after failure of Helicobacter pylori eradication with standard triple therapy. Dig Liver Dis 2003 35:711 15.
47. Beard CM, Noller KL, O'Fallon WM, Kurland LT, Dahlin DC. Cancer after exposure to metronidazole. Mayo Clin Proc 1988 63:147 53.